Core Insights - Orthofix reported strong performance in Q4 2025, with significant growth in Bone Growth Therapies and U.S. Limb Reconstruction, marking the eighth consecutive quarter of adjusted EBITDA growth [6] Sales Performance - Total global net sales for Q4 were $218.6 million, reflecting a 3% increase on a pro forma, constant-currency basis, excluding discontinued M6 artificial disc product lines [4] - The top 30 U.S. distributor partners contributed to a 25% year-over-year growth in net sales for Q4, with over 75% of U.S. net sales driven by these partners by Q4 2025 [1] Segment Performance - Global limb reconstruction net sales reached $38.0 million, driven by an 8% growth in the U.S. [2] - Bone Growth Therapies achieved Q4 net sales of $68.3 million, up 7%, benefiting from increased utilization and higher prescribing velocity [2] - Global spinal implants, biologics, and enabling technologies reported Q4 net sales of $112.3 million, supported by targeted distributor transitions [3] Product Developments - Orthofix plans to launch the VIRATA Spinal Fixation System in the second half of 2026, integrating it with the 7D navigation platform [7] - The company expects to introduce over a dozen products in the next 18 months, focusing on automation enhancements and technology-enabled advancements [9] Financial Metrics - Q4 pro forma non-GAAP adjusted gross margin was 71.4%, with a Q4 adjusted EBITDA of $29.2 million, representing 13.4% of net sales [10][11] - Free cash flow for Q4 was $16.8 million, with total cash at the end of the quarter amounting to $85.1 million [11] Future Guidance - For 2026, Orthofix guided net sales of $850 million to $860 million, implying approximately 5.5% pro forma constant-currency growth [12] - The company anticipates positive free cash flow for 2026, excluding potential legal settlements, and expects an adjusted gross margin of approximately 72.5% [13]

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [13] - Pro forma non-GAAP adjusted gross margin was 71.4%, reflecting the impact of the M6 discontinuation and productivity improvements [15] - Fourth quarter pro forma non-GAAP adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [14] - U.S. limb reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4][14] Market Data and Key Metrics Changes - U.S. limb reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The BGT business delivered fourth quarter growth of 7%, more than double the market rate [8] Company Strategy and Development Direction - The company is focused on enhancing its commercial execution and driving deeper market penetration of the 7D navigation system [8] - A strategic rebranding of the orthopedics business to limb reconstruction reflects a focus on high-value clinical categories, representing an estimated $2.6 billion market opportunity [6] - The company plans to launch the VIRATA Spinal Fixation System in the second half of 2026, which is expected to enhance surgical efficiency and serve as a multi-year growth catalyst [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth [11] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization [10] - Management highlighted the importance of maintaining disciplined execution and targeted capital allocation to achieve sustainable above-market growth [10][11] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [17] - Adjusted growth margins for the full year are expected to be approximately 72.5% [18] Q&A Session Summary Question: Clarification on CMS impact on BGT - The CMS change is expected to have a 1% impact in Q1 specific to BGT revenue only, which is immaterial for the year overall [32] Question: Long-range plan and margin improvement - Management indicated that the channel optimization initiative took longer to execute, but it is expected to strengthen the foundation for long-term value [34][37] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with U.S. limb reconstruction returning to double-digit growth in the second half of 2026 [42] Question: 7D placements and biologics portfolio - There was a 30% increase in 7D placements in 2025, and the biologics portfolio is expected to regain market pace as the commercial network is scaled [51][53] Question: Tariff impact on guidance - The company expects about a $1 million-$2 million impact from tariffs in 2026, which is included in the guidance [57] Question: Free cash flow improvement expectations - Free cash flow improvement from 2025 to 2026 is expected to be in the range of $7 million-$8 million, excluding legal settlements [60]

Q2 2025 Financial Performance - Pro Forma Net Sales reached $2007 million, a 35% year-over-year increase on a constant currency basis[18, 27, 28] - Non-GAAP Pro Forma Adjusted EBITDA was $206 million, representing 103% of pro forma net sales, compared to $166 million in Q2 2024[18, 30] - Non-GAAP Pro Forma Adjusted Gross Margin improved to 727%, compared to 713% in Q2 2024[18, 30] - Free Cash Flow was $45 million, showing continued positive year-over-year progress[18] Segment Performance - Bone Growth Therapies (BGT) net sales increased by 6% year-over-year[18, 23] - U S Spine Fixation net sales grew by 5% year-over-year, driven by a 7% increase in U S procedure volume[18, 24] - U S Orthopedics net sales saw a significant increase of 28% year-over-year, marking the fourth consecutive quarter of double-digit growth[18] Future Outlook - The company expects to be free cash flow positive for the full year 2025[36] - Full-year 2025 guidance includes Pro Forma Net Sales of $808 million to $816 million and Pro Forma Adjusted EBITDA of $82 million to $86 million[38]